#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
If you or someone you know struggles with cannabis dependence, new treatments are finally in development—because right now, there are zero FDA-approved medications to help.
ZME Science reports on the University at Buffalo study (Journal of Psychoactive Drugs) finding cannabis beverage users cut weekly alcohol intake from 7.02 to 3.35 drinks—nearly in half. Among 438 adults surveyed, 62.6% reduced or stopped drinking alcohol entirely, with fewer binge episodes reported. Researchers attribute the substitution to the familiar social format of holding a canned beverage. The cannabis beverage market has grown to $1B+, with 76% from hemp-derived products. Global projections suggest $4B by 2028. However, the Nov 2026 federal ban’s 0.4mg THC cap per container would eliminate most of these products.
“The fact that we have zero FDA-approved pharmacotherapies for cannabis use disorder while use rises across every demographic is a failure of investment priorities,the pipeline is finally catching up, and not a moment too soon.”
CANNABIS BEVERAGES AS ALCOHOL HARM REDUCTION
The UB study (Journal of Psychoactive Drugs): 438 adults who consumed cannabis beverages cut alcohol from 7 to 3.35 drinks/week. 62.6% reduced or stopped drinking. The familiar ‘can in hand’ format makes substitution psychologically easy.
The market is $1B+, projected $4B by 2028. But the Nov ban would cap THC at 0.4mg per container, eliminating virtually every cannabis beverage. We have peer-reviewed evidence these products reduce alcohol harm—a leading cause of preventable death. And the government is about to ban them.
Have thoughts on this? Share it:
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →